1-3 of 3
Niccolò Bartalucci
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera

Clinical Trials & Observations
Paola Guglielmelli, Giacomo Coltro, Francesco Mannelli, Giada Rotunno, Giuseppe G. Loscocco, Carmela Mannarelli, Chiara Maccari, Chiara Paoli, Simone Romagnoli, Niccolò Bartalucci, Alessandro M. Vannucchi
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2927–2931.
https://doi.org/10.1182/bloodadvances.2021006350
Published: 2022
Includes: Supplemental data
Journal Articles

Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR -mutated MPNs

Manjola Balliu, Laura Calabresi, Niccolò Bartalucci, Simone Romagnoli, Laura Maggi, Rossella Manfredini, Matteo Lulli, Paola Guglielmelli, Alessandro Maria Vannucchi
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2184–2195.
https://doi.org/10.1182/bloodadvances.2020003291
Published: 2021
Includes: Supplemental data
Journal Articles

RAS / CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features

Clinical Trials & Observations
Giacomo Coltro, Giada Rotunno, Lara Mannelli, Carmela Mannarelli, Sara Fiaccabrino, Simone Romagnoli, Niccolò Bartalucci, Enrica Ravenda, Eleonora Gelli, Emanuela Sant’Antonio, Mrinal M. Patnaik, Ayalew Tefferi, Alessandro M. Vannucchi, Paola Guglielmelli
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3677–3687.
https://doi.org/10.1182/bloodadvances.2020002175
Published: 2020
Includes: Supplemental data